Tumor Thickness at the Tumor-normal Interface: A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal Metastases
- 1 September 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Surgical Pathology
- Vol. 34 (9), 1287-1294
- https://doi.org/10.1097/pas.0b013e3181eb2f7b
Abstract
Progress in the treatment of hepatic colorectal metastases (HCRM) demands pathologic indicators of therapy response. We observed that a majority of residual tumor cells are seen at the tumor-normal interface (TNI) in resected HCRM specimens and hypothesized that tumor thickness at the TNI correlates with radiologic and pathologic response and recurrence-free survival (RFS). This study included 103 patients with HCRM resected after preoperative chemotherapy with or without bevacizumab. Imaging response was assessed by response evaluation criteria in solid tumors (RECIST) and recently described CT morphology criteria by Chun et al. The pathologic response was categorized as complete (no tumor cells), major (1 tumor, the average tumor thickness at the TNI was used. Sixty-five patients received oxaliplatin-based chemotherapy, 38 received irinotecan-based chemotherapy, and 75 received concurrent bevacizumab. A complete pathologic response was seen in 9 patients, a major response in 44, and a minor response in 50. Median tumor thickness at the TNI was 2.8 mm (interquartile range, 0.5 to 6 mm). Tumor thickness correlated better with radiologic response as determined by Chun et al (PConclusions Tumor thickness measured at the TNI is potentially a new prognostic factor for therapy response and survival outcome in patients with resected HCRM.Keywords
This publication has 19 references indexed in Scilit:
- Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver MetastasesJama-Journal Of The American Medical Association, 2009
- A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancerInternational Journal of Colorectal Disease, 2009
- Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal MetastasesJournal of Clinical Oncology, 2008
- Prognostic Value of Pathologic Complete Response After Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Long-Term Analysis of 566 ypCR PatientsInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Bilobar Colorectal Liver Metastases: Treatment OptionsSurgical Oncology Clinics of North America, 2008
- Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?Journal of Clinical Oncology, 2008
- Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal CancerSeminars in Oncology, 2006
- Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus StatementAnnals of Surgical Oncology, 2006
- High interstitial fluid pressure — an obstacle in cancer therapyNature Reviews Cancer, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerThe New England Journal of Medicine, 2004